Chinese Journal of Pharmacovigilance ›› 2011, Vol. 8 ›› Issue (9): 521-523.

Previous Articles     Next Articles

Clinical Efficacy Analysis of Amoxicillin/clavulanic Potassium Combined Levofloxacin in the treatment of multi-drug resistant tuberculosis (MDR-TB)

WANG Xiao, LIU Xing, WANG Lu   

  1. The Third People's Hospital of Kunming, Yunnan Kunming 650041, China
  • Received:2011-01-04 Online:2011-09-10 Published:2015-07-30

Abstract: Objective To observe and evaluate the clinical effect of amoxicillin/clavulanate potassium combined levofloxacin in multi-drug resistant tuberculosis(MDR-TB). Methods 101 cases of retreatment smear-positive MDR-TB patients were randomly divided into treatment group(52 patients) and control group(49 patients); chemotherapy: the treatment group based on amoxicillin/clavulanate potassium and levofloxacin, associated with pyrazinamide, ethambutol, aminosalicylic acid isoniazid and rifampicin spray bite; The control group based on levofloxacin, combination therapy is same with the treatment group; The treatment course of all cases is 12 months. Results 5 patients were terminated because of adverse drug reactions In the course of treatment, the treatment group actually completed 50 patients, the control group actually completed 46 patients. To the end of treatment, sputum conversion rate of treatment group and control group Separately was 78.0% and 56.5%, sputum conversion rate in the treated group was significantly higher than the control group(P <0.05); foci effective rate of treatment group was 78.0%, cavity closure rate was 82.0%, foci effective rate and cavity closure rate in treatment group were significantly higher than the control group(P <0.05). Conclusion amoxicillin/clavulanate potassium combined levofloxacin in the treatment of MDR-TB was contribute to sputum conversion and Absorption of the lesion, adverse drug reactions was low, worthy of clinical application.

Key words: amoxicillin/clavulanic potassium, levofloxacin, multi-drug resistant tuberculosis

CLC Number: